Core Insights - The health industry in China is entering a new technology-driven cycle, with significant growth from 7.4 trillion yuan to 12.3 trillion yuan over the past five years, highlighting the importance of technology and innovation in the sector [2][3]. Industry Trends - The "14th Five-Year Plan" has prioritized life and health as key areas for technological innovation, providing strong policy momentum for industry upgrades [3]. - The conference focused on various cutting-edge topics, including innovative drugs, brain-computer interfaces, AI in healthcare, and the transformation of traditional Chinese medicine [2]. Technological Advancements - The concept of "natural force" in health proposed by a leading academic emphasizes a shift from treating diseases to enhancing the body's natural capabilities, aligning with the industry's trend towards prevention and integration [6]. - Advances in rehabilitation technology are expected to make rehabilitation services more accessible for disabled individuals, promoting their participation in society [8]. AI and Healthcare Integration - AI technology is becoming a key solution for addressing challenges in the healthcare industry, with a particular focus on the modernization of traditional Chinese medicine [9]. - The integration of AI in medical practices is evolving from tool-based applications to ecosystem development, with companies exploring innovative solutions based on clinical needs [13][14]. Innovative Drug Development - The Chinese innovative drug market is experiencing significant growth, with licensing transactions reaching nearly 30%-40% of the global total, indicating strong international interest [18]. - The valuation logic for innovative drug companies is being redefined, with a notable increase in business development transactions and a surge in market confidence [20]. Market Performance - The "Dandelion 50" index in the healthcare sector has shown remarkable performance, with a year-to-date increase of approximately 29%, significantly outperforming other indices [20]. - The conference highlighted eight categories of innovative case studies, setting benchmarks for the industry in areas such as AI healthcare, biopharmaceuticals, and social psychological services [20].

Core Insights - The biomanufacturing industry in China is entering a historic policy window, driven by the inclusion of biomanufacturing in the "14th Five-Year Plan" and the implementation of the "Regulations on the Management of Clinical Research and Clinical Translation Applications of Biomedical New Technologies" [1][10] - Leading in vitro diagnostic company, Sansure Biotech, is aligning its strategic development with national policies, focusing on high-quality innovation and technological self-reliance to transition from "following innovation" to "source innovation" [1][2] Policy Direction and Strategic Layout - The combination of the "14th Five-Year Plan" and the new regulations provides strong support for the biomanufacturing industry, emphasizing high-quality innovation and technological independence [2] - Sansure Biotech is integrating AI technology into its diagnostic platform, establishing a vertical integration capability from raw materials to large-scale production and intelligent terminals [2][3] Product Development and Market Positioning - The company is enhancing its diagnostic capabilities in respiratory and HPV fields, ensuring precision in diagnosis while promoting convenient and home-based testing solutions [3][4] - Sansure Biotech has achieved significant growth in its sequencing business, with a 150% year-on-year increase in the first three quarters, and has received over 130 new domestic and international certifications this year [4] Competitive Advantages and Global Strategy - Sansure Biotech aims to become a platform-based ecological enterprise, focusing on "products + services + digital empowerment" to enhance its competitive edge [5][7] - The company is expanding its global market presence by implementing a strategy of "deepening emerging markets and breaking into high-end markets," with a focus on localized production and regional R&D centers [7][9] Innovation Goals and Future Outlook - The company has set clear innovation goals for the "14th Five-Year Plan," aiming to transition into a platform-based ecological enterprise driven by product, service, and digital empowerment [8][10] - Sansure Biotech plans to leverage national strategies and market demands, utilizing AI technology and ecological construction to capture opportunities in the global biomanufacturing landscape [10]

中泰证券（600918）认为，国内医疗器械行业处于持续快速发展阶段，短期医保控费和国际形势对医疗 器械领域可能带来负面扰动，但依然看好创新驱动下的进口替代以及全球化发展，当前时间点，预计多 重负面影响正在充分释放，器械板块已进入拐点区间，不同细分拐点节奏或有差异。持续看好：1)国产 企业在政策扶持以及创新驱动下，竞争力不断提升，加速进口替代；2)全球化布局完善，海外市场持续 突破的公司；3)重视AI医疗、脑机接口等主题投资机会。 方正证券认为，医疗器械行业进入调整周期尾声，行业及公司层面边际改善趋势明确，重视底部回升机 会。在医疗行业整顿、招标节奏延迟、集采扩面执行、医保控费等多重压力下，医疗器械板块股价持续 下调；2024年四季度设备更新的加速落地带来短期催化，但由于中标到收入确认存在周期，整体仍处于 底部波动，然而年初以来，该板块已出现一定回升趋势，一方面国家陆续出台政策支持高端创新器械发 展，同时管制价格"内卷"、优化国内招标采购环境，此外设备更新持续驱动采购需求释放；另一方面， 国产医疗器械企业业绩端压力因素逐步消化，加之出海业务的持续布局，二季度出现边际改善趋势。在 创新、出海和业绩修复的多重驱动下 ...

行业概览 2025/10 www.leadleo.com 2025年中国医疗大模型行业概览： 大模型铸就新引擎，赋能驱动大健康 China Medical Large Model Industry 中国医療用大規模モデル産業 报告标签：人工智能、AI医疗、大模型 主笔人：吕佳睿 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均系头豹研究院独有的高度机密性 文件（在报告中另行标明出处者除外）。 ，任何人不得以任何方式擅自 复制、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述约定的行为发生，头豹研究 院保留采取法律措施、追究相关人员责任的权利。头豹研究院开展的所有商业活动均使用"头豹研究院 "或"头豹"的商号、商标，头豹研究院无任何前述名称之外的其他分支机构，也未授权或聘用其他任何 第三方代表头豹研究院开展商业活动。 行业概览 | 2025/10 中国医疗大模型行业 ◼ 中国医疗大模型市场呈现"梯队分化、场景 深耕、生态协同"的竞争格局，行业正向临 床价值与商业化落地加速迈进 中国医疗大模型市场已形成以华为云、晶泰科 技、讯飞医疗、联影智能等为代表的第一梯队， 凭借技术壁垒与商业落地能力主 ...

Core Viewpoint - The launch of the Hang Seng Biotechnology Index futures on November 28 is expected to provide investors with new risk hedging tools and enhance liquidity in the biotechnology sector [1] Group 1: Index and Market Overview - The Hang Seng Biotechnology Index was launched by Hang Seng Indexes Company in 2019 to reflect the overall performance of the biotechnology sector in the Hong Kong stock market [1] - The index currently includes notable companies such as Innovent Biologics, BeiGene, WuXi Biologics, CanSino Biologics, and 3SBio, covering sub-sectors like CXO and innovative drugs [1] Group 2: Market Trends and Expectations - The introduction of the index futures is anticipated to attract foreign capital back to the biotechnology sector amid a global liquidity easing cycle initiated by the Federal Reserve's interest rate cuts [1] - The continuous inflow of southbound funds is expected to create a resonance effect, further boosting the biotechnology sector in the Hong Kong market [1]

Core Viewpoint - The trend of AI in healthcare is irreversible, with all AI-based medical products originating from clinical needs and ultimately providing greater value than clinical applications [2][4]. Group 1: AI in Healthcare - AI and large models are seen as tools that must address clinical problems effectively [2][3]. - Liu Jianxun, Senior Vice President of GeRui Technology, emphasizes that technology innovation must focus on solving real clinical issues [3][4]. - The company has made significant advancements in orthopedic fields, including the launch of a fully electric integrated intraoperative 3D imaging system and the "Newton" orthopedic endoscopic surgical robot, which is entering multi-center human clinical trials [2]. Group 2: Clinical Value and Innovation - The essence of AI medical innovation is to return to clinical fundamentals, ensuring that technology meets actual clinical needs [3][4]. - Liu Jianxun highlights the importance of accurately defining clinical needs to address genuine clinical pain points [3]. Group 3: Commercialization and Industry Ecosystem - Liu Jianxun stresses the need for a collaborative effort to improve the industry ecosystem, particularly regarding payment systems for innovative medical devices [4]. - He notes that a diversified payment system in international markets supports the promotion of innovative medical technologies, which should be emulated in China [4]. - The expectation is for all stakeholders, including medical institutions, enterprises, and insurance agencies, to explore solutions suitable for the Chinese market to foster healthy industry development [4].

Core Viewpoint - The AI medical sector experienced a significant increase of 3.48% on November 24, with leading stock performance from Sichuang Medical [1] Group 1: Market Performance - On November 24, the Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] - The top-performing stocks in the AI medical sector included Sichuang Medical, which rose by 8.20% to a closing price of 4.88, and Chengdu Xian Dao, which increased by 6.61% to 22.90 [1] Group 2: Trading Volume and Capital Flow - The AI medical sector saw a net inflow of 136 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 99.92 million yuan [1] - The trading volume for Sichuang Medical reached 2.345 million shares, with a transaction value of 1.11 billion yuan [1] Group 3: Individual Stock Capital Flow - Notable net inflows from institutional investors included 67.19 million yuan for Weining Health, 38.08 million yuan for Rundar Medical, and 33.69 million yuan for Jiuyuan Yinhai [2] - Conversely, retail investors showed net outflows in several stocks, including 47.88 million yuan for Weining Health and 55.12 million yuan for Jiuyuan Yinhai [2]

责任编辑：郭栩彤 关于板块后续可能的催化，龙宇飞认为可关注这几个方面的催化进展：一是整体AI应用领域的催化， 比如今年以来较大的催化其实是基于DeepSeek这种基础模型能力的提升；二是政策端，比如今年底地 方预算中有专项拨款做基础设施建设，或者定价上进一步明确；三是应用端，海内外出现解决问题能力 特别强的应用，比如解决了明确的临床问题或者创新药当中的瓶颈。 在AI医疗的相关细分领域中，龙宇飞指出，首先可重点关注传统医疗信息化企业转型AI，因为这类企 业在医院客户关系和渠道方面优势突出；其次是AI技术驱动的初创公司或上市公司，这类企业往往技 术领先，产品创新力强；再次，还可关注穿透药企/械企布局AI，比如一些CXO公司利用AI赋能研发， 他们的优势是深刻理解行业需求和拥有大量高质量数据。 免责声明：本通讯所载信息来源于本公司认为可靠的渠道和研究员个人判断，但本公司不对其准确性或 完整性提供直接或隐含的声明或保证。此通讯并非对相关证券或市场的完整表述或概括，任何所表达的 意见可能会更改且不另外通知。此通讯不应被接受者作为对其独立判断的替代或投资决策依据。本公司 或本公司的相关机构、雇员或代理人不对任何人使用此全 ...

Core Insights - The long-term investment opportunities in the medical device sector stem from innovation, international expansion, and mergers and acquisitions, with the sector's innovative and international capabilities being recognized and valuations being restructured [1] - In the short term, there are opportunities for performance and valuation recovery for individual stocks in Q4 and 2026, with some companies expected to accelerate growth in 2025 compared to 2024, and a potential performance inflection point in 2026 [1] Industry Performance - The medical device sector experienced significant year-on-year growth in revenue and net profit in Q3 2025, with ongoing recovery in bidding processes [1] - The high-value consumables segment is slowly recovering, and the procurement of electrophysiology and other related fields is gradually clearing [1] - The IVD segment is under pressure due to centralized procurement and the unbundling of testing packages, but some companies are experiencing high growth in overseas markets [1] Investment Recommendations - It is recommended to focus on innovative device segments with large market potential and low domestic penetration rates, such as PFA, RDN, TAVR, as well as new technology directions like brain-computer interfaces, AI in healthcare, and surgical robots [1] - The long-term outlook is positive for Chinese medical device companies to grow into global leaders through incremental innovation and internationalization [1] Index Information - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies in the medical device, medical services, and medical information sectors from the Shanghai and Shenzhen markets to reflect the overall performance of medical-themed listed companies [1] - The CSI Medical Index primarily focuses on the pharmaceutical and biotechnology sectors, emphasizing small and mid-cap companies, and exhibits notable cyclical volatility characteristics [1]

Core Insights - The report suggests that the current market position may be the starting point of a long-term bull market, supported by gradual improvements in fundamentals and industry highlights [3][4] - The report emphasizes the importance of time over space in the current bull market, indicating that the duration of the bull market may be more significant than the magnitude of the increase [3][4] Industry Research Construction Materials - The investment strategy focuses on three main lines: 1) Real estate chain recovery, emphasizing resilient consumer building material leaders like Dongfang Yuhong and Beixin Building Materials, which are expected to have greater profit elasticity amid rising demand for stock updates 2) Overseas growth, targeting companies with established advantages and mature operations abroad, such as Huaxin Cement and Conch Cement 3) Corporate transformation, highlighting construction companies actively restructuring and innovating during industry downturns, like Shanghai Port and Hongrun Construction [10] Machinery Manufacturing - The investment strategy revolves around three major themes: 1) Cycle recovery in engineering machinery, with internationalization, electrification, and intelligentization opening new growth spaces 2) Data center power generation equipment, driven by increased electricity demand 3) Nuclear fusion, entering a phase of capital expenditure expansion with high technical barriers [11] Company Research Aidi Precision (603638.SH) - Aidi Precision reported revenue of 2.37 billion yuan for Q1-Q3 2025, a year-on-year increase of 16.5%, and a net profit of 320 million yuan, up 12.6% year-on-year - The company is expected to benefit from the recovery in the engineering machinery sector, with continued growth in demand for its hydraulic components and new products like industrial robots and RV reducers [12] NetEase-S (9999.HK) - NetEase's Q3 2025 game revenue fell short of expectations due to the deferral of income recognition - The company maintains revenue forecasts of 114.5 billion yuan for 2025, 123.6 billion yuan for 2026, and 132.2 billion yuan for 2027, with a focus on new game releases expected to contribute significantly in 2026 [13] Yidu Technology (2158.HK) - Yidu Technology has made progress in AI medical innovation, but revenue forecasts for FY26 and FY27 have been reduced by 19.4% and 24.9% respectively - The company is expected to achieve a net profit of 0.08 billion yuan in FY28, maintaining a "buy" rating despite the adjustments [14] NVIDIA (NVDA.O) - NVIDIA's FY26 Q3 performance exceeded market expectations, with a projected GAAP net profit of $113.88 billion for FY2026 - The company has raised its FY2027-2028 net profit forecasts by 14.1% and 14.7%, driven by strong demand for AI computing [15] Lenovo Group (0992.HK) - Lenovo reported revenue of $20.452 billion for FY26 Q2, a 15% year-on-year increase, with adjusted net profit rising 25% - AI-related business revenue accounted for 30% of total revenue, up 13 percentage points year-on-year, despite downward adjustments in profit forecasts for FY26 to FY28 [16]